ABSTRACT
Chimeric antigen receptor (CAR) T cell therapy has made great progress in treating lymphoma, yet patient outcomes still vary greatly. The lymphoma microenvironment may be an important factor in the efficacy of CAR T therapy. In this study, we designed a highly multiplexed imaging mass cytometry (IMC) panel to simultaneously quantify 31 biomarkers from 13 patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) who received CAR19/22 T cell therapy. A total of 20 sections were sampled before CAR T cell infusion or after infusion when relapse occurred. A total of 35 cell clusters were identified, annotated, and subsequently redefined into 10 metaclusters. The CD4+ T cell fraction was positively associated with remission duration. Significantly higher Ki67, CD57, and TIM3 levels and lower CD69 levels in T cells, especially the CD8+/CD4+ Tem and Te cell subsets, were seen in patients with poor outcomes. Cellular neighborhood containing more immune cells was associated with longer remission. Fibroblasts and vascular endothelial cells resided much closer to tumor cells in patients with poor response and short remission after CAR T therapy. Our work comprehensively and systematically dissects the relationship between cell composition, state, and spatial arrangement in the DLBCL microenvironment and the outcomes of CAR T cell therapy, which is beneficial to predict CAR T therapy efficacy.
Subject(s)
Immunotherapy, Adoptive , Lymphoma, Large B-Cell, Diffuse , Receptors, Chimeric Antigen , Single-Cell Analysis , Tumor Microenvironment , Humans , Immunotherapy, Adoptive/methods , Tumor Microenvironment/immunology , Lymphoma, Large B-Cell, Diffuse/therapy , Lymphoma, Large B-Cell, Diffuse/immunology , Single-Cell Analysis/methods , Receptors, Chimeric Antigen/metabolism , Receptors, Chimeric Antigen/immunology , Female , Male , Treatment Outcome , Middle Aged , Adult , Biomarkers, Tumor , AgedABSTRACT
We describe a simple aptamer assay for the rapid analysis of aflatoxin B1 (AFB1), a potently carcinogenic fungal metabolite. The original anti-AFB1 aptamer was rationally truncated, obtaining a short aptamer that displayed better performance. Different concentrations of AFB1 were detected by measuring the circular dichroism spectra of this short aptamer. The detection limit reached 0.6 nM, which was lower than that of the original aptamer (80 nM).
Subject(s)
Aptamers, Nucleotide , Biosensing Techniques , Aflatoxin B1/analysis , Circular Dichroism , Food Contamination/analysis , Limit of DetectionABSTRACT
Despite the importance and promise of cancer vaccines for broader prevention and treatment of cancer, limited clinical responses are observed, suggesting that key rational designs are required for inducing potent immune responses against cancer. Here we report a mesoporous silicon vector (MSV) as a multi-functional microparticle for formulating an efficient cancer vaccine composed of B16 melanoma derived-tyrosinase related protein 2 (TRP2) peptide and dual toll-like receptor (TLR) agonists. We demonstrated that MSV microparticles protected the peptide from rapid degradation for prolonged antigen presentation to immune cells. Moreover, MSV enabled co-delivery of two different TLR agonists [CpG oligonucleotide and monophosphoryl lipid A (MPLA)] along with TRP2 peptide into the same dendritic cell (DC), thus increasing the efficiency and capacity of DCs to induce potent TRP2-specifc CD8+ T cell responses against B16 melanoma. Furthermore, this MSV-based DC vaccine could significantly prolong the median survival of tumor-bearing mice by orchestrating effective host immune responses involving CD8+ T cells, CD4+ T cells and macrophages. Our study provides rational and potentially translational approach to develop durable and potent immunotherapy for patients with cancer by delivering various combinations of tumor antigens, neoantigens and innate immune agonists.
Subject(s)
Cancer Vaccines/administration & dosage , Dendritic Cells , Lipid A/analogs & derivatives , Melanoma, Experimental/therapy , Membrane Proteins/administration & dosage , Oligodeoxyribonucleotides/administration & dosage , Peptide Fragments/administration & dosage , Silicon/administration & dosage , Toll-Like Receptors/agonists , Animals , Antigens, Neoplasm/administration & dosage , Female , Immunotherapy , Ligands , Lipid A/administration & dosage , Melanoma, Experimental/immunology , Mice, Inbred C57BL , Toll-Like Receptors/immunologyABSTRACT
Type I interferon (IFN) is critical for controlling pathogen infection; however, its regulatory mechanisms in plasmacytoid cells (pDCs) still remain unclear. Here, we have shown that nucleic acid sensors cGAS-, STING-, MDA5-, MAVS-, or transcription factor IRF3-deficient mice produced high amounts of type I IFN-α and IFN-ß (IFN-α/ß) in the serum and were resistant to lethal plasmodium yoelii YM infection. Robust IFN-α/ß production was abolished when gene encoding nucleic acid sensor TLR7, signaling adaptor MyD88, or transcription factor IRF7 was ablated or pDCs were depleted. Further, we identified SOCS1 as a key negative regulator to inhibit MyD88-dependent type I IFN signaling in pDCs. Finally, we have demonstrated that pDCs, cDCs, and macrophages were required for generating IFN-α/ß-induced subsequent protective immunity. Thus, our findings have identified a critical regulatory mechanism of type I IFN signaling in pDCs and stage-specific function of immune cells in generating potent immunity against lethal YM infection.
Subject(s)
Adaptive Immunity/immunology , Dendritic Cells/immunology , Interferon Type I/immunology , Malaria/immunology , Signal Transduction/immunology , Animals , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Gene Knockdown Techniques , Mice , Mice, Knockout , Plasmodium yoelii , Polymerase Chain ReactionABSTRACT
Epigenetic factors have been implicated in the regulation of CD4(+) T-cell differentiation. Jmjd3 plays a role in many biological processes, but its in vivo function in T-cell differentiation remains unknown. Here we report that Jmjd3 ablation promotes CD4(+) T-cell differentiation into Th2 and Th17 cells in the small intestine and colon, and inhibits T-cell differentiation into Th1 cells under different cytokine-polarizing conditions and in a Th1-dependent colitis model. Jmjd3 deficiency also restrains the plasticity of the conversion of Th2, Th17 or Treg cells to Th1 cells. The skewing of T-cell differentiation is concomitant with changes in the expression of key transcription factors and cytokines. H3K27me3 and H3K4me3 levels in Jmjd3-deficient cells are correlated with altered gene expression through interactions with specific transcription factors. Our results identify Jmjd3 as an epigenetic factor in T-cell differentiation via changes in histone methylation and target gene expression.
Subject(s)
CD4-Positive T-Lymphocytes/enzymology , Cell Differentiation , Jumonji Domain-Containing Histone Demethylases/metabolism , Animals , CD4-Positive T-Lymphocytes/cytology , Cells, Cultured , Jumonji Domain-Containing Histone Demethylases/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Th1 Cells/cytology , Th1 Cells/enzymology , Th17 Cells/cytology , Th17 Cells/enzymology , Th2 Cells/cytology , Th2 Cells/enzymologyABSTRACT
Toll-like receptor (TLR) mediated recognition of pathogen associated molecular patterns allows the immune system to rapidly respond to a pathogenic insult. The "danger context" elicited by TLR agonists allows an initially non-immunogenic antigen to become immunogenic. This ability to alter environment is highly relevant in tumor immunity, since it is inherently difficult for the immune system to recognize host-derived tumors as immunogenic. However, immune cells may have encountered certain TLR ligands associated with tumor development, yet the endogenous stimulation is typically not sufficient to induce spontaneous tumor rejection. Of special interest are TLR5 agonists, because there are no endogenous ligands that bind TLR5. CBLB502 is a pharmacologically optimized TLR5 agonist derived from Salmonella enterica flagellin. We examined the effect of CBLB502 on tumor immunity using two syngeneic lymphoma models, both of which do not express TLR5, and thus do not directly respond to CBLB502. Upon challenge with the T-cell lymphoma RMAS, CBLB502 treatment after tumor inoculation protects C57BL/6 mice from death caused by tumor growth. This protective effect is both natural killer (NK) cell- and perforin-dependent. In addition, CBLB502 stimulates clearance of the B-cell lymphoma A20 in BALB/c mice in a CD8(+) T cell-dependent fashion. Analysis on the cellular level via ImageStream flow cytometry reveals that CD11b(+) and CD11c(+) cells, but neither NK nor T cells, directly respond to CBLB502 as determined by NFκB nuclear translocation. Our findings demonstrate that CBLB502 stimulates a robust antitumor response by directly activating TLR5-expressing accessory immune cells, which in turn activate cytotoxic lymphocytes.
Subject(s)
Adjuvants, Immunologic/pharmacology , Flagellin/chemistry , Lymphocytes/drug effects , Lymphocytes/immunology , Lymphoma, T-Cell/immunology , Peptides/pharmacology , Toll-Like Receptor 5/agonists , Adaptive Immunity/drug effects , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/therapeutic use , Animals , Cell Line, Tumor , Cytokines/blood , Immunity, Innate/drug effects , Lymphoma, T-Cell/blood , Lymphoma, T-Cell/drug therapy , Mice , Peptides/chemistry , Peptides/therapeutic use , Perforin/metabolism , Up-Regulation/drug effectsABSTRACT
OBJECTIVE: To evaluate the clinical significance of fertility-preserving comprehensive staging surgery (CSS) in the treatment of malignant ovarian germ cell tumors (MOGCTs). METHODS: A total of 92 cases of MOGCTs were retrospectively reviewed. RESULTS: Forty-six patients (50%) received CSS, which includes ipsilateral adnexectomy+omentectomy+retroperitoneal lymphadenectomy (appendectomy and multiple biopsies as required). Forty-six patients (50%) received USO, which includes ipsilateral adnexectomy+clinical intraoperative evaluation (including retroperitoneal lymph nodes, great omentum, peritoneal, and contralateral ovary), biopsy of suspicious sites, and excision of all visible lesions. The mean operation time (177.0 vs. 114.8 min; p<0.0001) and the mean intraoperative blood loss (499.1 ml vs. 112.9 ml; p=0.04) were significantly higher in the CSS group compared to those in the USO group. The complication rate (17.4% vs 0%, p=0.003), the relapse rate (10.9% vs 2.2%, p=0.102) and the mortality rate (4.3% vs 2.2%, p=0.500) were higher in the CSS group compared to those in the USO group. The difference in complication rate was statistically significant. The overall 5 year survival rates were 92% and 97% in the CSS and USO groups, respectively (p=0.575). Tumor-free survival rates at 5 years were 87% and 97% in the CSS and USO groups, respectively (p=0.115). CONCLUSIONS: The benefit of fertility-preserving CSS to MOGCT patients was not greater than that of USO. It is safer and more effective to perform ipsilateral adnexectomy+clinical intraoperative exploration surgery (including retroperitoneal lymph nodes, great omentum, peritoneal, and contralateral ovary), biopsy of suspicious sites, excision of all visible lesions, and adjuvant chemotherapy.
Subject(s)
Fertility Preservation , Neoplasms, Germ Cell and Embryonal/pathology , Neoplasms, Germ Cell and Embryonal/surgery , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Adult , Female , Gynecologic Surgical Procedures , Humans , Lymph Node Excision , Neoplasm Staging , Ovariectomy , Pregnancy , Pregnancy Outcome , Retrospective Studies , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: To investigate the operative treatment for first-treated patients with malignant ovarian germ cell tumors who need preservation of fertility. METHODS: The clinical data of 105 patients who were treated with fertility-sparing surgery in 11 hospitals from 1992 to 2010 were collected to evaluate the outcomes of different primary surgical operative procedures. All 105 cases were performed the surgeries that preserved fertility and divided into three groups according to the surgical approaches, comprehensive staging surgery group: 47 cases (44.8%) received comprehensive staging surgeries that including the ipsilateral oophorectomy + omentectomy + retropertoneal lymph node dissection ± appendectomy + multiple biopsies;oophorectomy group:45 cases (42.9%)received ipsilateral oophorectomy ± biopsy of contralateral ovary ± omentectomy;tumor resection group:13 cases (12.4%) received enucleation of the mass with preservation of the ovary. Differences were compared among the three groups of patients in the surgery-related indicators, complications, fertility and prognosis. RESULTS: (1) Surgery-related indicators:the average blood loss of the comprehensive staging surgery group, the oophorectomy group and the tumor resection group were 496, 104 and 253 ml, the mean operation time were 176, 114 and 122 minutes, respectively, and there were significant differences among three groups (P = 0.011, P = 0.000). (2) Complication:the surgical complication rates of the three groups were 17% (8/47), 0 and 1/13, with significant differences (P = 0.015). (3) Reproductive function status: the pregnancy rate and birth rate of the three groups were no significant differences (9/19 vs. 7/19 vs. 2/3, P = 0.515; 8/19 vs. 5/19 vs. 2/3, P = 0.636). (4) PROGNOSIS: the recurrence rate of the three groups were significant differences [13% (6/47) vs. 0 vs. 2/13, P = 0.013], but the death rate with no significant differences [6% (3/47) vs. 0 vs. 0, P = 0.129]; The five-year survival rate of three different groups were 89%, 100% and 100% (P > 0.05), while disease free survival rate were 85%, 100% and 83% (P < 0.05), respectively. CONCLUSIONS: Compared with comprehensive staging surgery, oophorectomy group have higher surgical security and satisfactory prognosis, considerable pregnancy rates and birth rate. The tumor resection security may be reliable, but the prognosis is poor.
Subject(s)
Fertility Preservation , Neoplasms, Germ Cell and Embryonal/surgery , Ovarian Neoplasms/surgery , Ovariectomy/methods , Adolescent , Adult , Biopsy, Needle , Chemotherapy, Adjuvant , Child , Child, Preschool , Disease-Free Survival , Female , Gynecologic Surgical Procedures/methods , Humans , Lymph Node Excision , Neoplasm Recurrence, Local , Neoplasm Staging , Neoplasms, Germ Cell and Embryonal/mortality , Neoplasms, Germ Cell and Embryonal/pathology , Omentum/pathology , Omentum/surgery , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Pregnancy , Pregnancy Rate , Retrospective Studies , Survival Rate , Young AdultABSTRACT
Allogeneic hematopoietic cell transplantation is an established treatment for hematologic and other malignancies. Donor-derived immune cells can identify and attack host tumor cells, producing a graft-versus-tumor (GVT) effect that is crucial to the treatment. Using multiple tumor models and diverse donor-host combinations, we have studied the role of granzyme B (GzmB) in GVT effect. We first confirmed previous findings that GzmB deficiency diminished the ability of a high dose of CD8(+) T cells to cause lethal graft-versus-host disease. However, when GVT studies were performed using a moderate cell dose that the hosts could tolerate, GzmB(-/-) CD8(+) T cells demonstrated a significantly enhanced GVT effect. GzmB-mediated, activation-induced cell death in wild-type CD8(+) T cells was found responsible for their reduced GVT activity. Conversely, GzmB(-/-) CD8(+) T cells exhibited enhanced expansion, skewed toward an effector or effector memory phenotype, and produced higher amounts of IFN-γ and Fas ligand that might contribute to GzmB-independent tumor control. These findings demonstrate for the first time, to our knowledge, that GzmB-mediated damage of CD8(+) T cells impairs the desired GVT effect. This study suggests that inhibiting donor-derived GzmB function may represent a promising strategy to improve GVT effect without exacerbating graft-versus-host disease.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Graft vs Tumor Effect/physiology , Granzymes/physiology , Animals , Apoptosis/immunology , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/immunology , Cell Division , Cell Line, Tumor/transplantation , Fas Ligand Protein/biosynthesis , Fas Ligand Protein/genetics , Fas Ligand Protein/immunology , Graft vs Host Disease/etiology , Graft vs Host Disease/immunology , Granzymes/deficiency , Granzymes/genetics , Immunologic Memory , Interferon-gamma/biosynthesis , Interferon-gamma/genetics , Interferon-gamma/immunology , Lymphocyte Activation , Lymphoma/immunology , Lymphoma/pathology , Lymphoma/surgery , Mice , Mice, Inbred Strains , Radiation Chimera , Tumor BurdenABSTRACT
Allogeneic hematopoietic cell transplantation is an established treatment for hematologic and nonhematologic malignancies. Donor-derived immune cells can identify and attack host tumor cells, producing a graft-versus-tumor (GVT) effect that is crucial to the effectiveness of the transplantation therapy. CBLB502 is a novel agonist for TLR5 derived from Salmonella flagellin. On the basis of TLR5-mediated immunomodulatory function, we examined the effect of CBLB502 on GVT activity. Using two tumor models that do not express TLR5, and thereby do not directly respond to CBLB502, we found that CBLB502 treatment significantly enhanced allogeneic CD8(+) T cell-mediated GVT activity, which was evidenced by decreased tumor burden and improved host survival. Importantly, histopathologic analyses showed that CBLB502 treatment did not exacerbate the moderate graft-versus-host disease condition caused by the allogeneic CD8(+) T cells. Moreover, mechanistic analyses showed that CBLB502 stimulates CD8(+) T cell proliferation and enhances their tumor killing activity mainly indirectly through a mechanism that involves the IL-12 signaling pathway and the CD11c(+) and CD11b(+) populations in the bone marrow cells. This study demonstrates a new beneficial effect of CBLB502, and suggests that TLR5-mediated immune modulation may be a promising approach to improve GVT immunity without exacerbating graft-versus-host disease.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Flagellin/pharmacology , Graft vs Tumor Effect/drug effects , Hematopoietic Stem Cell Transplantation , Immunity, Cellular/drug effects , Neoplasms, Experimental/therapy , Salmonella/chemistry , Toll-Like Receptor 5/agonists , Animals , CD8-Positive T-Lymphocytes/pathology , Cell Proliferation/drug effects , Flagellin/chemistry , Flagellin/immunology , Graft vs Host Disease/immunology , Graft vs Host Disease/pathology , Graft vs Tumor Effect/immunology , Immunity, Cellular/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred DBA , Neoplasms, Experimental/immunology , Neoplasms, Experimental/pathology , Toll-Like Receptor 5/immunology , Transplantation, HomologousABSTRACT
AIM: For full-scale analysis of Human Papillomavirus (HPV) status in humans, two minor groove binder (MGB)-based one-step multiplex real-time PCR systems were developed: one to screen 16 high-risk HPV (HR-HPV) types, and one to screen a broader spectrum of HPV types (common HPV or C-HPV). METHODS: Sensitivity and specificity were evaluated using diluted reference plasmids and 20 control human DNA samples. For clinical evaluation, 510 cervical scrape samples were evaluated. RESULTS: The sensitivity assays revealed that the C-HPV detection system could detect 10 ~ 100 plasmid copies/reaction, while the HR-HPV detection system detected 10 ~ 500 copies. The specificity test revealed that the systems did not yield positive signals from the 20 human genomic DNA samples. Performance was tested on 510 usable clinical samples. The HR-HPV results were compared to those from the Hybrid Capture 2 (HC2) test, which assesses 13 HR-HPV types; the concordance level between the two methods was 90.8% with a kappa value of 0.813. CONCLUSIONS: These results showed that our novel MGB-based one-step multiplex real-time PCR method may be used for the diagnosis and mass screening of HPV in clinical and large-scale epidemiological studies.
Subject(s)
Human Papillomavirus DNA Tests/methods , Multiplex Polymerase Chain Reaction/methods , Papillomaviridae/genetics , Papillomavirus Infections/diagnosis , Cervix Uteri/virology , DNA Probes, HPV/genetics , DNA, Viral/chemistry , DNA, Viral/genetics , DNA, Viral/isolation & purification , Female , Humans , Papillomaviridae/classification , Papillomavirus Infections/virology , Reproducibility of Results , Sensitivity and Specificity , Sequence Analysis, DNAABSTRACT
TNF-α and its two receptors (TNFR1 and 2) are known to stimulate dendritic cell (DC) maturation and T cell response. However, the specific receptor and mechanisms involved in vivo are still controversial. In this study, we show that in response to an attenuated mouse hepatitis virus infection, DCs fail to mobilize and up-regulate CD40, CD80, CD86, and MHC class I in TNFR1(-/-) mice as compared with the wild-type and TNFR2(-/-) mice. Correspondingly, virus-specific CD8 T cell response was dramatically diminished in TNFR1(-/-) mice. Adoptive transfer of TNFR1-expressing DCs into TNFR1(-/-) mice rescues CD8 T cell response. Interestingly, adoptive transfer of TNFR1-expressing naive T cells also restores DC mobilization and maturation and endogenous CD8 T cell response. These results show that TNFR1, not TNFR2, mediates TNF-α stimulation of DC maturation and T cell response to mouse hepatitis virus in vivo. They also suggest two mechanisms by which TNFR1 mediates TNF-α-driven DC maturation, as follows: a direct effect through TNFR1 expressed on immature DCs and an indirect effect through TNFR1 expressed on naive T cells.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cell Differentiation/immunology , Coronavirus Infections/immunology , Dendritic Cells/immunology , Dendritic Cells/pathology , Murine hepatitis virus/immunology , Receptors, Tumor Necrosis Factor, Type I/physiology , Tumor Necrosis Factor-alpha/physiology , Adoptive Transfer , Amino Acid Sequence , Animals , CD8-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/virology , Cells, Cultured , Coronavirus Infections/genetics , Coronavirus Infections/pathology , Dendritic Cells/virology , Dose-Response Relationship, Immunologic , Immunodominant Epitopes/administration & dosage , Immunodominant Epitopes/genetics , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Molecular Sequence Data , Murine hepatitis virus/genetics , Receptors, Tumor Necrosis Factor, Type I/deficiency , Receptors, Tumor Necrosis Factor, Type I/genetics , Receptors, Tumor Necrosis Factor, Type II/deficiency , Receptors, Tumor Necrosis Factor, Type II/genetics , Receptors, Tumor Necrosis Factor, Type II/physiology , Tumor Necrosis Factor-alpha/metabolismABSTRACT
A critical step for avian influenza viruses to infect human hosts and cause epidemics or pandemics is acquisition of the ability of the viral hemagglutinin (HA) to bind to human receptors. However, current global influenza surveillance does not monitor HA binding specificity due to a lack of rapid and reliable assays. Here we report a computational method that uses an effective scoring function to quantify HA-receptor binding activities with high accuracy and speed. Application of this method reveals receptor specificity changes and its temporal relationship with antigenicity changes during the evolution of human H3N2 viruses. The method predicts that two amino acid differences at 222 and 225 between HAs of A/Fujian/411/02 and A/Panama/2007/99 viruses account for their differences in binding to both avian and human receptors; this prediction was verified experimentally. The new computational method could provide an urgently needed tool for rapid and large-scale analysis of HA receptor specificities for global influenza surveillance.
Subject(s)
Hemagglutinin Glycoproteins, Influenza Virus/metabolism , Influenza A Virus, H3N2 Subtype/metabolism , Receptors, Virus/metabolism , Animals , Humans , Protein BindingABSTRACT
Fulminant hepatitis can cause acute liver failure and death in both humans and mice. However, the cellular and molecular mechanisms underlying the acute disease are still not well understood. Here, we examine the role of Th17 response in the development of the acute hepatitis following infection with mouse hepatitis virus (MHV). We show that IL-17 levels in serum are rapidly elevated and positively correlated to liver damage and death of the mice. In IFN-γR(-/-) mice, Th17 response is enhanced and the elevated IL-17 production contributes to severe liver damage as well as detrimental inflammation because neutralization of IL-17 effectively suppresses inflammation and protects mice from liver injury. We further show that IFN-γ facilitates antigen-induced apoptosis of Th17 cells and adoptive transferred IFN-γR(-/-), but not IFN-γR(+/+); CD4(+) T cells promotes an enhanced liver damage in wild-type mice. The results demonstrate an essential role of Th17 cells in MHV-induced immunopathology and the importance of IFN-γ in maintaining immune balance between Th1 and Th17 responses during acute viral infection.
Subject(s)
Hepatitis, Viral, Animal/immunology , Interferon-gamma/immunology , Murine hepatitis virus/immunology , Th17 Cells/immunology , Animals , Apoptosis/drug effects , CD4-Positive T-Lymphocytes/immunology , Hepatitis, Viral, Animal/pathology , Inflammation/immunology , Interferon-gamma/genetics , Interferon-gamma/pharmacology , Interleukin-17/blood , Interleukin-17/immunology , Liver/immunology , Liver/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Survival Analysis , Th17 Cells/cytologyABSTRACT
OBJECTIVE: To identify the potential neoplastic risk in gonadal development abnormality with Y chromosome. METHODS: Inquiries about the illness history were made. Lymphocyte chromosomal karyotype of peripheral blood was analyzed. Sex determining region Y gene and relative steroids and enzymes were detected. Gonadal site was examined through medical imaging. Gonadal excision was performed by laparotomy or laparoscopy. Pathological examinations were done on all of the specimens. RESULTS: Among 41 cases of androgen insensitive syndrome, spermatogenic cell neoplasm occurred in 1 patient, sertoli cell tumor in 2, and interstitial cell hyperplasia in 5. Among 14 cases of 17 alpha-hydroxylase deficiency (XY) syndrome, one was sertoli cell tumor, and one was sertoli cell hyperplasia. In 4 cases of XY pure gonadal dysgenesis, one was gonadoblastoma with dysgerminoma. One of 16 cases of XO/XY gonadal dysgenesis was spermatogenic cell neoplasm with agenda cell tumor. Four cases of testes degeneration were all with dysgenetic testes. All of the gonadoblastoma and germ-cell tumor were located in the pelvis. Tumors occurred mostly during 15 years of age to 32 years. CONCLUSIONS: The gonads of XY pure gonadal dysgenesis has high risks of gonadoblastoma and germ-cell tumor. The older the onset age after puberty, the higher the malignancy risk is. Once diagnosed, bilateral gonads should be excised as soon as possible.
Subject(s)
Androgen-Insensitivity Syndrome/genetics , Chromosomes, Human, Y/genetics , Gonadal Dysgenesis, 46,XY/genetics , Gonadoblastoma/genetics , Ovarian Neoplasms/genetics , Adolescent , Adult , Age Factors , Androgen-Insensitivity Syndrome/complications , Androgen-Insensitivity Syndrome/surgery , Child , Child, Preschool , Female , Gonadal Dysgenesis/complications , Gonadal Dysgenesis/genetics , Gonadal Dysgenesis/surgery , Gonadal Dysgenesis, 46,XY/complications , Gonadal Dysgenesis, 46,XY/surgery , Gonadoblastoma/etiology , Gonadoblastoma/prevention & control , Humans , Karyotyping , Male , Ovarian Neoplasms/etiology , Ovarian Neoplasms/prevention & control , Risk Factors , Sex Chromosome Aberrations , Young AdultABSTRACT
CD4+CD25+ regulatory T cells (Treg) have been shown to maintain immune tolerance against self and foreign Ags, but their role in persistent viral infection has not been well-defined. In this study, we investigated whether and where CD4+CD25+ Treg contribute to the development of chronic hepatitis B (CHB). One hundred twenty-one patients were enrolled, including 16 patients with acute hepatitis B, 76 with CHB, and 29 with chronic severe hepatitis B. We demonstrated that in chronic severe hepatitis B patients, the frequencies of CD4+CD25+ Treg in both PBMC and liver-infiltrating lymphocytes were significantly increased and there was a dramatic increase of FoxP3(+)-cell and inflammatory cell infiltration in the liver compared with healthy controls. In CHB patients, circulating CD4+CD25+ Treg frequency significantly correlates with serum viral load. In acute hepatitis B patients, circulating CD4+CD25+ Treg frequency was initially low and with time, the profile reversed to exhibit an increased number of circulating Treg in the convalescent phase and restored to normal levels upon resolution. In PBMC taken from infected patients, depletion of CD4+CD25+ Treg led to an increase of IFN-gamma production by HBV-Ag-stimulated PBMC. In addition, CD4+CD25+ Treg were capable of suppressing proliferation of autologous PBMC mediated by HBV Ags, which probably reflects the generation of HBV-Ag-specific Treg in circulation and in the liver of HBV-infected patients. Together, our findings suggest that CD4+CD25+ Treg play an active role not only in modulating effectors of immune response to HBV infection, but also in influencing the disease prognosis in patients with hepatitis B.
Subject(s)
Antibodies, Viral/biosynthesis , Hepatitis B virus/immunology , Hepatitis B/immunology , Hepatitis B/virology , Receptors, Interleukin-2/biosynthesis , Severity of Illness Index , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , Acute Disease , Adult , Alanine Transaminase/blood , Antibodies, Viral/blood , CD4 Lymphocyte Count , DNA, Viral/blood , Disease Progression , Epitopes, T-Lymphocyte/immunology , Female , Forkhead Transcription Factors/biosynthesis , Forkhead Transcription Factors/blood , Forkhead Transcription Factors/genetics , Hepatitis B/metabolism , Hepatitis B/pathology , Hepatitis B Surface Antigens/blood , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/metabolism , Hepatitis B, Chronic/pathology , Hepatitis B, Chronic/virology , Humans , Immunophenotyping , Inflammation Mediators/metabolism , Male , Middle Aged , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Interleukin-2/blood , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/virology , T-Lymphocytes, Regulatory/enzymology , T-Lymphocytes, Regulatory/pathology , Up-Regulation/immunology , Viral LoadABSTRACT
OBJECTIVE: To investigate the efficiency of positron emission tomography (PET) with (fluorine-18)-2-deoxyglucose ((18)FDG) in diagnosis of recurrent ovarian cancer. METHODS: (18)FDG-PET scanning and computerized tomography (CT) were performed on 31 patients 35 times, who were clinically free of disease after optimal cytoreductive surgery and first-line chemotherapy. Twenty-two patients were confirmed pathologically after second-look or re-debulking operation and the others were followed up by many methods (ultrasonography, CA(125) and pelvic examination combined), evaluating the role of PET and CT in the diagnosis of recurrent ovarian cancer. RESULTS: (1) PET demonstrated recurrent sites through increased (18)FDG uptake. In 35 times, PET showed 1 false-negative and 1 false-positive cases. (2) The sensitivity of (18)FDG-PET is 96.3%, and CT is 70.4%. There was significant difference between two groups (P < 0.05). CONCLUSION: PET is more sensitive in diagnosing recurrent ovarian cancer than CT, so it improve early diagnosis in recurrent ovarian cancer.